Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Liang, Y. [1 ]
Krupsky, K. [2 ]
Lankin, J. [2 ]
Cohn, J. [2 ]
Kashine, N. [2 ]
Honomichl, R. [2 ]
Rattigan-Brown, Y. [1 ]
Shehu, A. [1 ]
Salomonsen, R. [1 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Oracle Life Sci, Austin, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
early-stage NSCLC; osimertinib; physician preferences;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.02
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [1] Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non-small cell lung cancer and mutated EGFR
    Perez, Alejandro Vila
    Alegre-del Rey, Emilio J.
    Fenix-Caballero, Silvia
    Spacirova, Zuzana
    Varela, Petra Rosado
    Lima, Antonio Olry de Labry
    SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
  • [2] Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Planchard, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1780 - 1782
  • [3] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [4] Adjuvant Osimertinib in Resected EGFR-Mutated Stage IBeIIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
    Herbst, R. S.
    Wu, Y. -L.
    Grohe, C.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S. -W.
    Yu, C. -J.
    Vu, H. V.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E4 - E4
  • [5] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [6] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [7] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [8] Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
    Patel, Shruti R.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1631 - 1635
  • [9] Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non–small cell lung cancer and mutated EGFR
    Alejandro Vila Pérez
    Emilio J. Alegre-del Rey
    Silvia Fénix-Caballero
    Zuzana Špacírová
    Petra Rosado Varela
    Antonio Olry de Labry Lima
    Supportive Care in Cancer, 2024, 32
  • [10] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
12345